ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2156

Smoking Status Predicts Earlier SLICC Damage Index Progression in a Large SLE Cohort

Trevor McKown1, Rachna Unnithan1, Nnenna Ezeh1, Ting Ye2 and Christie M. Bartels1, 1Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, 2Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, systemic lupus erythematosus (SLE) and tobacco use

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Tobacco smoking predisposes to certain specific manifestations of systemic lupus erythematosus (SLE); however, less is known about smoking and cumulative organ damage in SLE. Our study aimed to examine the relationship of smoking history and pack-year exposure on rates of end-organ damage in a cohort of SLE patients.

Methods: Observational study in a cohort of 631 consecutive SLE patients at a single academic institution. Patients with at least one ambulatory rheumatology encounter and an ICD-9 or -10 code for SLE between 2008 and 2016 were identified. Electronic health records (EHR) were manually abstracted and patients meeting either ACR 1987 or SLICC 2012 classification criteria for SLE were included in analysis. The primary outcomes examined were median time to SLICC damage index (SLICC-DI) increase or death during the study period. The primary explanatory variable was ever smoking, defined as current or former smoking as ascertained from the EHR. Covariates examined included age at diagnosis, sex, race, ethnicity, area deprivation index (a marker of neighborhood poverty), number of SLE criteria, and SLICC-DI at time of study entry. Kaplan-Meier survival analysis was used to compare time to DI increase between ever-smokers and never-smokers. Multivariate analysis was performed using a Cox proportional hazards model.

Results: Compared to never-smokers, ever-smokers in the cohort were older at SLE diagnosis and at time of entry into the study (44.7 years vs 44.5, p<0.01; 55.9 years vs. 51.9, p<0.01). There were no significant differences in sex (88% female in ever-smokers vs 92% in never-smokers, p=0.41), race (83% white vs 82%, p=0.25) or Hispanic ethnicity (5% vs 3%, p= 0.92). Among 517 patients with SLICC-DI of 0 at the start of observation, the median time to increase in SLICC-DI was 61.7 months in ever-smokers (95% CI, 50.8 – 75.1) and 97.9 months in never-smokers (95% CI, 74.6 – 121.6), as shown in Figure 1. Age at SLE diagnosis (HR 1.03 per year, 95% CI 1.02 – 1.04) and greater than 10 pack-year smoking history (HR 1.43 compared to never-smokers, 95% CI 1.02 – 2.01) were significant predictors of earlier SLICC-DI increase in an adjusted Cox model.

Conclusion: Current or past smoking predicted earlier progression of cumulative organ damage in this cohort of SLE patients, with ever-smokers first developing organ damage about 3 years earlier than never-smokers. Further work is needed to replicate findings in more diverse cohorts, and to examine the effects of tobacco cessation on damage accrual.

Figure 1: Kaplan-Meier survival curve showing probability of freedom from SLICC-DI increase by smoking exposure in patients with no previously accrued damage (SLICC-DI = 0) at time of study entry.


Disclosure: T. McKown, None; R. Unnithan, None; N. Ezeh, None; T. Ye, None; C. M. Bartels, Pfizer, Inc., 2.

To cite this abstract in AMA style:

McKown T, Unnithan R, Ezeh N, Ye T, Bartels CM. Smoking Status Predicts Earlier SLICC Damage Index Progression in a Large SLE Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/smoking-status-predicts-earlier-slicc-damage-index-progression-in-a-large-sle-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/smoking-status-predicts-earlier-slicc-damage-index-progression-in-a-large-sle-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology